RUNX1 and leukemia: To test this, we knocked down Runx1 in multiple models—c-Kit+ bone marrow progenitors from Srsf2P95H and U2AF1S34F mice, K562 with SRSF2P95H and KO52 leukemia cells that naturally harbor SRSF2P95H—and measured CHK1 inhibitor sensitivity.